Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dermal Tolerability of Dapsone Gel
NCT02117752Phase 1Completed
- Sponsor
- Almirall
- Start
- Apr 2014
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of dapsone in acne vulgaris (2 arms), sponsored by Almirall. Primary endpoints: Mean Cumulative Irritation Index During Induction Phase at 21 days and Incidence of Sensitization Reactions During Challenge Phase at 6 weeks. Started Apr 2014; status: completed.
02
Drugs
dapsone
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT02117752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02117752.